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oal-ANTITRYPSIN (AAT), a glycoprotein
synthesized in the liver, is responsible
for about 9000 of the inhibitory capa-
city of human serum for trypsin, and
also for the inhibition of other proteolytic
enzymes such as elastase, collagenase and
leucocyte proteases. Synthesis of AAT is
controlled by a pair of genes at one locus
for which as many as 24 alleles have been
described. These alleles are inherited in an
autosomal codominant manner. They are
responsible for the different structural
variants of the AAT molecule, which can
be detected by their different electro-
phoretic mobilities. The Z, or slowest
variantt, in either its homozygous or
heterozygous form, may be the cause of a
deficiency ofAAT in the serum.
AAT deficiency has been shown to be
associated with a variety of diseases, but
particularly with chronic obstructive pul-
monary disease (Ganrot et al., 1967) and
liver disease (Berg and Eriksson, 1972;
Feldman et al., 1974; Sharp, 1976). The
latter takes the form of cholestatic
jaundice in infancy (neonatal hepatitis),
childhood cirrhosis and, less often, cirrho-
sis in adults. In addition, a few cases of
hepatocellular (11CC) or cholangiocellular
cancer have been described in patients
with homozygous (ZZ) or heterozygous
(MZ) AAT deficiency (Ganrot et al., 1967;
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Berg and Eriksson, 1972; Eriksson and
Hiagerstrand, 1974; Aagenaes et al., 1974;
Lieberman, 1974; Rawlings, et al., 1974;
Williams and Fajardo, 1974; Lieberman
et al., 1975; Zwi et al., 1975). A character-
istic finding in individuals with both
homozygous or heterozygous AAT defic-
iency, in the presence or absence of liver
disease, is the accumulation of periodic
acid-Schiff (PAS)-positive, diastase-resist-
ant globules in periportal hepatocytes
(Sharp, 1971). These globules consist of
aggregates of an asialo-antitrypsin within
the dilated endoplasmic reticulum
(Eriksson and Larsson, 1975).
The frequency with which AAT defic-
iency predisposes to HCC, ifindeed it does
so, is not known. In 2 retrospective
studies (Norkin and Campagna-Pinto,
1968; Berg and Eriksson, 1972) for the
presence of PAS-positive, diastase-
resistant globules in the liver of patients
with HCC, a prevalence of about 10% was
found. Both studies were conducted in
populations in which this tumour is rare.
Just how important AAT deficiency is as a
cause of HCC in those parts of the world
where the tumour is common has not yet
been established. We have measured
serum AAT concentrations by trypsin
inhibitory capacity (STIC) or radial im-
munodiffusion (RID), determined AAT
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phenotypes by acid-starch electrophoresis,
and looked for PAS-positive diastase-
resistant globules in the livers and tum-
ours of a series of southern African blacks
with HCC.
Seventy-seven unselected adult black
patients with histologically proven HCC
were studied. All but 4 of the patients
were males. Blood was taken at the time of
diagnosis and before treatment was begun.
STIC was measured by the benzoyl-
arginine-p-nitroanilide method ofErlanger
et al. (1961) in 60 patients and serum AAT
concentrations by RID (Schulman, 1973)
in the remaining 17 patients. AAT pheno-
typing was determined in all patients by
acid-starch electrophoresis as described by
Fagerhol (1968). Non-tumorous liver tissue
(normal or cirrhotic) and tumour tissue
obtained from each patient either by
percutaneous biopsy or at laparotomy or
necropsy were stained with PAS after
treatment with diastase and counter-
stained with haematoxylin. All the slides
were prepared by one technician in a
single session. A section from the liver of a
patient with proven AAT deficiency and
known to have PAS-positive diastase-
resistant globules in the hepatocytes was
included with the other slides as a control.
The sections were then examined for PAS-
positive inclusion globules. In patients
with H1CC and AAT deficiency, PAS-
positive diastase-resistant globules are
found in the malignant hepatocytes as
well as in the non-tumorous liver tissue
(Lieberman et al., 1975). The non-tumor-
ous liver tissue is cirrhotic in about 6000
of our patients with HCC.
Control values for serum AAT concen-
trations by RID, and AAT phenotyping,
were established in 630 black male blood
donors, while those for STIC were deter-
mined in 100 healthy young adult black
males.
STIC values in 60 HCC patients ranged
from 1P40 to 3-18 mg trypsin inhibited per
ml of serum, with a mean of 2 77 (the
normal range is 1P0 to 1 7 mg/ml serum).
All but one patient had a concentration
greater than 1P7 mg/ml serum. In the
remaining 17 patients, AAT concentrations
determined by RID ranged from 270 to
450 mg%0 with a mean of 386 (the normal
range is 180 to 320 mg00). With one
exception, the values were greater than
320mg%0.
No case of homozygous Z phenotype of
AAT was found by acid-starch electro-
phoresis. The phenotype distribution was
similar to that found in the controls, in
whom were also no hotnozygous Z pheno-
types. Although not encountered in this
group of healthy blacks, the Z phenotype
does occur in this population (Prinsloo and
Turnbull, unpublished).
In none of the HCC patients were
intracytoplasmic PAS-positive, diastase-
resistant globules observed, either in non-
tumorous liver tissue or in the tumour.
In a prospective study using chemical,
electrophoretic and histological criteria,
we could find no case of AAT deficiency in
77 unselected black patients with HCC. It
is therefore highly unlikely that AAT
deficiency plays a major role in the aetio-
logy of this tumour, which occurs so
commonly in southern African blacks.
Our findings are at variance with those of
Berg and Eriksson (1972) and Norkin and
Campagna-Pinto (1968), the former study-
ing European and the latter American
patients. There are 2 possible explana-
tions for this. Firstly, the PAS-positive
globules in the livers of their patients may
have consisted of some substance other
than AAT in the cytoplasm of the hepato-
cytes (Dekker and Krause, 1973; Palmer
et al., 1974). To be certain that these
globules contain AAT, it is necessary to
use either a specific immunofluorescent
technique on the tissues, using fluorescein-
labelled anti-human AAT (Delellis et al.,
1972) or the immunoperoxidase method
(Palmer and Wolfe, 1976). This was not
done in the 2 studies cited. As both were
retrospective analyses, neither chemical
estimations ofSTIC orAAT concentrations
by RID, nor AAT phenotyping, were
carried out on the patients' serum to
confirm AAT deficiency. The second
possible reason for the discrepant results
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is that HCC may be multifactorial in
aetiology and that the tumour has differ-
ent causes in different parts of the world.
AAT deficiency could be an occasional
cause of the tumour in most parts of the
world where HCC occurs sporadically, but
it is not a numerically important cause in
southern Africa, and possibly not else-
where in Africa or in the Far East where
this tumour is common.
As we did not perform crossed-electro-
phoresis in phenotyping our patients, it
may be argued that heterozygote Z pheno-
types might have been missed. The results
of the chemical and histological studies
make this unlikely. Lieberman and his co-
workers (1975) have seen only one MZ
patient with an STIC greater than 1-3 mg
trypsin inhibited per ml of serum and this
was found shortly after a partial hepatec-
tomy had been performed. All but 2 of
our patients had STIC or AAT concentra-
tions by RID above the upper limit of
normal, and it is doubtful that a MZ or
even a FZ phenotype would have achieved
these levels. PAS-positive diastase-resist-
ant globules were present in all ofEriksson
and Hagerstrand's large series of patients
with AAT deficiency (Eriksson and
Hagerstrand, 1974). These globules were
not demonstrable in the 2 patients in
the present series with normal serum AAT
concentrations or, indeed, in any of the
patients.
With 2 exceptions, our patients had
high AAT levels. AAT concentrations are
known to rise in the blood during the
course of malignant disease (Clark et al.,
1948). It has been suggested that the
increase in AAT is an attempt by the body
to defend itself against the spread and
progression of cancer (Goetz et al., 1972;
O'Neill, 1974). Were this so, individuals
with AAT deficiency might be expected to
have an increased susceptibility to all
forms ofmalignancy, and not only to HCC.
Alternatively, high AAT values might
simply reflect a non-specific acute-phase
response to tissue injury or inflammation.
The authors acknowledge the support of the
National Cancer Association of South Africa. The
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